A new day for precision oncology
A new world of NGS
Next-Generation Solution for Genomic Profiling
The Oncomine Precision Assay on the Ion Torrent Genexus System features a complete next-generation sequencing (NGS) testing workflow. Now every lab can go from specimen to report in a single day, providing a comprehensive genomic profile at a speed never possible before*.
This allows you to deliver NGS results at the same time as other single-gene methods, such as immunohistochemistry (IHC). The hands-off, set-up-and-go workflow makes NGS accessible, even if your lab is new to the technology.
With the lowest sample input requirement of any NGS solution, you can successfully sequence more precious samples—even when tissue is very limited.
Register for the New CAPToday Webinar
Ion Torrent Genexus System
Introducing the first turnkey NGS system that automates the specimen-to-report workflow and delivers results in a single day.
With just 10 minutes of hands-on time and two touchpoints, users can get up and running quickly with significantly less training. This highly flexible system lets you cost-effectively process samples as they come in - even just one.
Oncomine Precision Assay
The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes based on the latest therapy developments, medical guidelines, and clinical trials. Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from plasma or lysate derived from FFPE samples, giving you a wide range of utility. All of this is provided with a one-day turnaround time and a highly automated workflow on the Genexus System.
Don't let precious samples go untested
Did you know that some NGS send-out labs have test failure rates of 20% due to their high input requirement?1-4 At that rate, 1 out of every 5 samples will not pass due to lack of tissue, and many more are never submitted for testing at all.
Not with Oncomine Solutions. You can experience a sequencing success rate of over 95% because we only require 10ng of nucleic acid input. That means you can get an NGS result for most of the precious samples you have.
Maximize your ability to detect key biomarkers
Curated Pan-Cancer Content
- Mutation, CNV and fusion variant types across 50 key genes
- Driver and resistance variants
Fusion Sync Detection
- Sensitive and specific – targeted isoform designs
- Novel fusion detection
Molecular Tagging
- Enhanced low-level variant detection
- Key for liquid biopsy testing
Tissue and Plasma
- One test, one workflow, multiple sample types
FusionSyncTM Detection Technology
Gene fusions are an increasingly important target in precision oncology. Oncomine assays are superior for both sequencing success rate and sensitivity, two critical factors for fusion detection. Even when the tissue is very limited or the variants exist at low levels in the sample, you can detect key fusions by combining:
• Targeted known fusion detection
• Non-targeted detection of novel fusion combinations
• Novel fusion detection
Register for The Pathologist Webinar on March 26, 2020 to learn more about FusionSync detection technology https://thepathologist.com/webinar/hear-both-sides-of-the-fusion-detection-story
Oncomine Reporter
The Oncomine Reporter delivers clear and concise reports that present all relevant variants with annotated information about targeted therapies, guidelines, and enrollment of ongoing clinical trials.
The report is customizable so that you can tailor it to fit your team's needs.
NGS Expert Opinions on the Genexus System
Dr. Nicola Normanno from Naples and Dr. Philip Jermann from Basel share their opinion on how the new Genexus NGS System can help new laboratories adopt NGS, and also how expert labs can benefit from its speed and simplicity.
Dr. Jose Costa Describes His Experience
Hear from Dr. Jose Costa of IPATIMUP in Portugal, whose lab was the first to implement the Genexus System.
Webinar
Introducing a New World of NGS: One-Day, Hands-Free Solution to Fit in Any Lab
- Learn how the Genexus System addresses key challenges to NGS adoption.
- See the next-generation solution for genomic profiling of cancer samples.
- Hear about the experience of the first laboratory to implement this solution.
Speakers:
Dr. Jose Costa, IPATIMUP Dr. Andy Felton, Thermo Fisher Scientific
Request a Demonstration
Are you ready to experience the power of the Oncomine Precision Assay on the Genexus System? Request a demonstration today and our representatives will contact you shortly.
References:
1. Next-Generation Sequencing in 305 Consecutive Patents: Clinical Outcomes and Management Changes; Gregory J. Kubicek, MD., et al., Journal of Clinical Oncology, Aug. 2019.
2. J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
3. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer; Jason Zhu, et al.; Urologic Cancer: Seminars and Original Investigations, July 2019.
4. Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine™ TML and FoundationOne™ assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Heeke S. et al. DOI: 10.1158/1538-7445.AM2019-4889; July 2019.
For Research Use Only. Not for use in diagnostic procedures. *Specimen-to-report workflow will be available after the Ion Torrent Genexus Purification System and integrated reporting capabilities are added in 2020.
Trademarks | Terms and Conditions | Privacy Notices
© 2020 Thermo Fisher Scientific Inc. All Rights Reserved.
Select Your Location
United Kingdom
United States